Franz von Nussbaum

Nuvisan (Germany) — Germany

Medicine · Health Sciences

30h-index3.5kcitations177works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(32), Microtubule and mitosis dynamics(31), Crystallization and Solubility Studies(24), X-ray Diffraction in Crystallography(24), Microbial Natural Products and Biosynthesis(23)

Publications177 total

Identification of NUV-244 as a PNPLA3 I148M degrading small molecule
iScience·2025· 1 citedOpen Access
Opening the Door to a New Treatment Paradigm: The Re-emergence of Chymase Inhibitors
Journal of Medicinal Chemistry·2025
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling
Cell chemical biology·2024· 9 cited
European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe**
ChemMedChem·2023· 5 citedOpen Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Dominik Mumberg(20), Philip Lienau(14), Michael Brands(13), Gerhard Siemeister(13), Karl Ziegelbauer(11), Hans Briem(10), Benjamin Bader(9), Ulf Bömer(9), Antje M. Wengner(8), Dieter Häbich(6), Knut Eis(6), Lars Wortmann(6), Julien Lefranc(6), Arne Scholz(6), Stuart Ince(6), Simon J. Holton(6), Wölfgang Steglich(6), Dirk Kosemund(5), Martina Schäfer(5), Stefan Prechtl(5)